PM
JAZZ icon

Parametrica Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Parametrica Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,359
Closed -$212K – 248
2022
Q1 		$212K Buy
+1,359
New +$197K 0.16% 189

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Parametrica Management's JAZZ Position: Q2 2022 in Review

Parametrica Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 1,359 shares — an estimated $212K sold.

Parametrica Management first reported a position in JAZZ in Q1 2022 and held it in 1 quarter. The position peaked at $212K in Q1 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

  • Parametrica Management reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Parametrica Management sold 1,359 Jazz Pharmaceuticals shares in Q2 2022, an estimated $212K.
  • Parametrica Management first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Parametrica Management's Jazz Pharmaceuticals position peaked at $212K in Q1 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on Parametrica Management's 13F filing for Q2 2022, filed 22 Jul 2022.